Standard Biotools INC

Standard BioTools Inc. has filed an amendment to its Form 8-K, officially filing the Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc.

Standard BioTools Inc. announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10 million and a $30 million buyout of contingent payments from Illumina, facilitating its merger with Treeline Biosciences.

Standard BioTools Inc. received a notification from Nasdaq indicating it does not meet the minimum bid price requirement for continued listing on the Global Select Market.

Standard BioTools Inc. and Treeline Biosciences, Inc. announced a definitive merger agreement, combining to form Treeline Biosciences, a public biopharma company focused on advancing Treeline's pipeline.

Standard BioTools Inc. has officially regained compliance with Nasdaq's minimum bid price requirement.

Standard BioTools Inc. announced a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay, with vesting scheduled over two years.

Standard BioTools Inc. reported a widened net loss in Q3 2025, driven by restructuring charges and a decline in revenue, while progressing with the divestiture of its SomaScan Business.

Standard BioTools Inc. reported a reduced net loss in Q2 2025, driven by lower operating expenses and the strategic divestiture of its SomaScan business to Illumina for up to $425 million.

Standard BioTools' Q1 2025 revenue decreased by 10% year-over-year, reflecting ongoing integration efforts and shifts in sales mix.

Standard BioTools' Q3 2024 results reflect a significant increase in revenue and a net loss, heavily influenced by the recent merger with SomaLogic.

Standard BioTools' Q2 2024 results reflect the impact of the SomaLogic merger, including increased revenue and operating expenses, alongside restructuring efforts.

Standard BioTools' first quarter of 2024 saw a significant revenue increase of 81% year-over-year, primarily driven by the acquisition of SomaLogic.

Standard BioTools Inc.'s 2024 10-K filing reveals a year of strategic consolidation marked by the SomaLogic merger and Sengenics acquisition, aiming to enhance its life science tools portfolio.

Standard BioTools has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance, along with updated certifications from its CEO and CFO.

Standard BioTools Inc. outlines its share structure, voting rights, and corporate governance policies in its latest 10-K filing, including details on common and preferred stock.

Michael Egholm, President & CEO and a Director of Standard Biotools Inc., reported a transaction in 362,625 shares of common stock on August 3, 2026.

Standard BioTools Inc. amends its prior 8-K filing to include the Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc.

Standard BioTools Inc. announced the sale of its Mass Cytometry business to Multiplex Bio, a company led by advanced imaging industry veterans, with an expected closing by the end of 2026.

Standard BioTools Inc. announced the sale of its Mass Cytometry business to Multiplex Bio for $5 million and a $30 million buyout from Illumina, facilitating its merger with Treeline Biosciences.

Hanjoon Alex Kim, Chief Financial Officer of Standard Biotools Inc., reported a transaction in 202,476 shares of common stock on July 23, 2026.

Standard BioTools announced the filing of a registration statement for its merger with Treeline Biosciences, projecting over $900 million in combined cash and highlighting Treeline's clinical-stage pipeline.

Standard BioTools Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026, with several key proposals for shareholder vote.

Standard BioTools Inc. has filed a definitive proxy statement with the SEC.

Standard BioTools is asking stockholders to approve an amendment to its 2011 Equity Incentive Plan to increase the number of shares available for issuance by 17,400,000.

Madryn Investment Management withdraws its director nominees and proposal to declassify the board at Standard BioTools' upcoming annual meeting, leading to an updated proxy statement and a new WHITE proxy card.

Standard BioTools highlights 2023 achievements, including revenue growth and cost reductions, while facing a proxy fight from Madryn Health Partners at the upcoming annual meeting.

Viking Global Investors has entered into a voting agreement to support Standard BioTools' merger with Treeline Biosciences.

Casdin Capital has entered into a voting and lock-up agreement to support the proposed merger between Standard BioTools Inc. and Treeline Biosciences, Inc.

Casdin Capital and affiliated funds have increased their beneficial ownership in Standard BioTools Inc. to 24.2% through recent open market purchases.

Casdin Capital and its affiliates have increased their beneficial ownership in Standard BioTools Inc. to 20.4%, with Eli Casdin holding 21.6%, following recent share acquisitions and the conversion of preferred stock, reinforcing their strategic investment in the company after its merger with SomaLogic.

Investment firm MAK Capital and Michael A. Kaufman have reported a 6.7% beneficial ownership stake in Standard BioTools Inc.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott as a reporting person.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman jointly reported beneficial ownership of 5.19% of Standard BioTools Inc.'s common stock.